Alzheimer’s Disease/Dementia News

Lecanemab reduced amyloid markers and slowed cognitive decline in patients with early Alzheimer’s disease, although not without risk for adverse events, according to new data published in The New England Journal of Medicine.

Klotho protein levels in cerebrospinal fluid and plasma were associated with clinical stages of Alzheimer’s disease, cognitive decline, and amyloid and tau burden, independent of KL-VS heterozygosity status, according to research.

Researchers at Emory University are developing a visual tool to view how conditions such as Alzheimer's disease and autism spectrum disorder affect the brain in real-time, the university announced in a press release.

A practical risk score tool has been developed to help people identify their potential risk for dementia, researchers reported in JAMA Network Open.

A team of researchers at the University of Miami Miller School of Medicine have developed an online platform of metrics designed to assess a patient’s risk for developing Alzheimer’s disease and other neurological issues.

BrainCheck Inc. has received a $1.5 million grant award from the Small Business Innovation Research program, which it will use to fund a study of CARE, its digital cognitive care management platform, the company announced in a news release.

Gantenerumab, a treatment for mild cognitive impairment due to Alzheimer’s disease, did not meet the primary endpoint of slowing cognitive decline in a phase 3 clinical trial, Genentech announced in a released statement.

For adults in the U.K., preexisting neuropsychiatric conditions and having a prescription for a related treatment carried a significantly increased risk of severe outcomes from COVID-19 and other severe acute respiratory infections.

Cerveau Technologies Inc. has announced a license agreement with Lexeo Therapeutics Inc. that will allow Lexeo to use an investigational imaging agent from Cerveau for the assessment of neurofibrillary tangles in the brain.

CHICAGO — Impairments in decision-making may be among the earliest signs of cognitive decline, according to a presenter at the 2022 American Neurological Association annual meeting.